Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.42 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL66496 | 1.00 | BRD4 (0.43) | BRD4GRIN2BS1PR1S1PR5OPRM1 | |
| SCHEMBL3527474 | 0.85 | GRIN2B (0.45) | BRD4GRIN2BS1PR1S1PR5OPRM1 | |
| SCHEMBL2692741 | 0.82 | S1PR5 (0.47) | GRIN2BS1PR1S1PR5OPRM1ACHE | |
| SCHEMBL2692744 | 0.82 | S1PR5 (0.47) | GRIN2BS1PR1S1PR5OPRM1ACHE | |
| SCHEMBL2692748 | 0.82 | S1PR5 (0.47) | GRIN2BS1PR1S1PR5OPRM1ACHE | |
| SCHEMBL3617880 | 0.82 | S1PR5 (0.47) | GRIN2BS1PR1S1PR5OPRM1ACHE | |
| SCHEMBL16498046 | 0.80 | CACNA1B (0.39) | GRIN2BBCHEKDM4E | |
| SCHEMBL16053729 | 0.79 | ALDH1A1 (0.38) | BRD4S1PR1S1PR5OPRM1ACHE | |
| SCHEMBL19100375 | 0.78 | GBA1 (0.51) | GRIN2BS1PR1S1PR5OPRM1ACHE | |
| SCHEMBL19063783 | 0.78 | GBA1 (0.51) | GRIN2BS1PR1S1PR5OPRM1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070270417-A1 | Antibacterial Agents | GLAXO GROUP LIMITED (GB) | 2007-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070270417-A1 | Antibacterial Agents | NQO2, NQO1, NDUFV2 | BRD4 340/4885GRIN2B 4649/4885S1PR1 4479/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.